The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Open accessAbstract
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, BRAF inhibitors led to a monotherapy response rate of >50% in BRAFV600E melanoma and ~30% in BRAFV600E NSCLC, but only ~5% in BRAFV600E colorectal cancer, likely due to the variable robustness of adaptive feedback networks in each tumor type (45–49).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,003
Detection of BRAF V600 Mutations in Metastatic Melanoma
Qu, K. Z., Pan, Q., Zhang, X., Rodríguez, L. R., Zhang, K., Li, H., Ho, A. K., Sanders, H. R., Sferruzza, A. D., Cheng, S.-M., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.07.003 · Cited by 59
SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor
Kaplan, F. M., Kugel, C. H., Dadpey, N., Shao, Y., Abel, E. V., & Aplin, A. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.390906 · Cited by 60
Klinac, D., Gray, E. S., Freeman, J. B., Reid, A. L., Bowyer, S. E., Millward, M., & Ziman, M. R. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-423 · Cited by 60
Advanced stage melanoma therapies: Detailing the present and exploring the future
Luther, C. A., Swami, U., Zhang, J., Milhem, M. M., & Zakharia, Y. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.11.002 · Cited by 61
Systemic Therapies for Advanced Melanoma
Bomar, L., Senthilnathan, A., & Ahn, C. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2019.05.001 · Cited by 59
Gaining momentum: New options and opportunities for the treatment of advanced melanoma
Michielin, O. A., & Höeller, C. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.012 · Cited by 60
Perera, E., Gnaneswaran, N., Jennens, R. R., & Sinclair, R. D. (2013) · Healthcare · doi:10.3390/healthcare2010001 · Cited by 61
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
Leight, J. L., Tokuda, E. Y., Jones, C. E., Lin, A. J., & Anseth, K. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505662112 · Cited by 58
Uveitis in Patients With Late-Stage Cutaneous Melanoma Treated With Vemurafenib
Guedj, M., Quéant, A., Funck‐Brentano, E., Kramkimel, N., Lellouch, J., Monnet, D., Longvert, C., Gantzer, A., & Brézin, A. P. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.3024 · Cited by 58
Wen, Y., Li, J., Koo, J., Shin, S., Lin, Y., Jeong, B., Mehnert, J. M., Chen, S., Cohen-Solal, K., & Goydos, J. S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1531 · Cited by 59
Self-citationp53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
Krayem, M., Journé, F., Wiedig, M., Morandini, R., Najem, A., Salès, F., van Kempen, L. C. L. T., Sibille, C., Awada, A. H., Marine, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.002 · Cited by 61
Liu, S., Nikanjam, M., & Kurzrock, R. (2016) · Oncotarget · doi:10.18632/oncotarget.7023 · Cited by 59
Cooper, Z. A., Reuben, A., Spencer, C. N., Prieto, P. A., Austin-Breneman, J. L., Jiang, H., Haymaker, C., Gopalakrishnan, V., Tetzlaff, M. T., Frederick, D. T., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1136044 · Cited by 59
Self-citationAMPK promotes tolerance to Ras pathway inhibition by activating autophagy
Sanduja, S., Feng, Y., Mathis, R. A., Sokol, E. S., Reinhardt, F., Halaban, R., & Gupta, P. B. (2016) · Oncogene · doi:10.1038/onc.2016.70 · Cited by 59
Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients
Lee, A. Y., Nicolás Droppelmann, M., Panageas, K. S., Zhou, Q. C., Ariyan, C. E., Brady, M. S., Chapman, P. B., & Coit, D. G. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5642-0 · Cited by 58
Richtig, G., Höeller, C., Kashofer, K., Aigelsreiter, A. M., Heinemann, A., Kwong, L. N., Pichler, M., & Richtig, E. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15436 · Cited by 60
Exploring liver cancer biology through functional genetic screens
Wang, C., Cao, Y., Yang, C. G., Bernards, R., & Qin, W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00465-x · Cited by 58
Vemurafenib and ipilimumab: New agents for metastatic melanoma
Banaszynski, M., & Kolesar, J. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120260 · Cited by 57
Wroblewski, D., Mijatov, B., Mohana‐Kumaran, N., Lai, F., Gallagher, S. J., Haass, N. K., Zhang, X. D., & Hersey, P. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs330 · Cited by 60
Self-citationDossett, L. A., Ben-Shabat, I., Bagge, R. O., & Zager, J. S. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5150-2 · Cited by 57
New drug targets in metastatic melanoma
Homet, B., & Ribas, A. (2013) · The Journal of Pathology · doi:10.1002/path.4259 · Cited by 58
Self-citationCrystal Structure of a Promoter Sequence in the B-raf Gene Reveals an Intertwined Dimer Quadruplex
Wei, D., Todd, A. K., Zloh, M., Gunaratnam, M., Parkinson, G. N., & Neidle, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4101358 · Cited by 57
Signal Transduction in Human Cutaneous Melanoma and Target Drugs
Uzdensky, A. B., Demyanenko, S. V., & Bibov, M. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313080004 · Cited by 57
Delgado‐Goñi, T., Miniotis, M. F., Wantuch, S., Parkes, H. G., Marais, R., Workman, P., Leach, M. O., & Beloueche‐Babari, M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0068 · Cited by 58
Pérez‐Alea, M., McGrail, K., Sánchez‐Redondo, S., Fábrega, B. F., Fournet, G., Cortés, J., Muñoz‐Couselo, E., Hernández‐Losa, J., Tenbaum, S. P., Martin, G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.160 · Cited by 57
Adaptive resistance to RAF inhibitors in melanoma
Kugel, C. H., & Aplin, A. E. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12264 · Cited by 58
Update on the Targeted Therapy of Melanoma
Johnson, D. B., & Sosman, J. A. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0226-8 · Cited by 56
Self-citationThe Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness
Cabaço, L. C., Tomás, A., Pojo, M., & Barral, D. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887366 · Cited by 60
Chemotherapy‐induced peripheral neurotoxicity ( CIPN ): what we need and what we know
Cavaletti, G. (2014) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12073 · Cited by 58
Identification of PLX 4032‐resistance mechanisms and implications for novel RAF inhibitors
Choi, J., Landrette, S. F., Wang, T. L., Evans, P., Bacchiocchi, A., Bjornson, R. D., Cheng, E., Stiegler, A. L., Gathiaka, S. M., Acevedo, O., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12197 · Cited by 58
Resistance to Chemotherapy: Patient Variability and Cellular Heterogeneity
Kessler, D. A., Austin, R. H., & Levine, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0118 · Cited by 59
Wolf, A. M., Zia, S. Y., Verma, R., Pavlick, A. C., Wilson, M. A., Golfinos, J. G., Silverman, J. S., & Kondziolka, D. S. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2072-6 · Cited by 56
Self-citationConjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors
Glass, L. R. D., Lawrence, D. P., Jakobiec, F. A., & Freitag, S. K. (2016) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000833 · Cited by 56
Self-citationTargeting BRAF pathway in low-grade serous ovarian cancer
Perrone, C., Angioli, R., Luvero, D., Giannini, A., Donato, V. D., Cuccu, I., Muzii, L., Raspagliesi, F., & Bogani, G. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2024.35.e104 · Cited by 56
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
Sánchez-Torres, J. M., Viteri, S., Molina‐Vila, M. Á., & Rosell, R. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.04.01 · Cited by 56
Serasinghe, M. N., Missert, D. J., Asciolla, J. J., Podgrabinska, S., Wieder, S. Y., Izadmehr, S., Belbin, G. M., Skobe, M., & Chipuk, J. E. (2014) · Oncogene · doi:10.1038/onc.2014.21 · Cited by 58
Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem
Belum, V. R., Fischer, A., Choi, J. N., & Lacouture, M. E. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0308-6 · Cited by 56
Flaherty, L. E., Hamid, O., Linette, G. P., Schuchter, L. M., Hallmeyer, S., Gonzalez, R. C., Cowey, C. L., Pavlick, A. C., Kudrik, F. J., Curti, B. D., et al. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000024 · Cited by 55
Self-citationGenomics of gallbladder cancer: the case for biomarker-driven clinical trial design
Sicklick, J. K., Fanta, P. T., Shimabukuro, K. A., & Kurzrock, R. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9602-8 · Cited by 56
Melanoma and the Unfolded Protein Response
Sykes, E. K., Mactier, S., & Christopherson, R. I. (2016) · Cancers · doi:10.3390/cancers8030030 · Cited by 58
Current status and future direction in the management of malignant melanoma
Gladfelter, P., Darwish, N. H. E., & Mousa, S. A. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000379 · Cited by 55
68 Ga-DOTA-GGNle-CycMSH hex targets the melanocortin-1 receptor for melanoma imaging
Yang, J., Xu, J., Gonzalez, R. C., Lindner, T., Kratochwil, C., & Miao, Y. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau4445 · Cited by 55
Self-citationWang, V. E. H., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2779 · Cited by 57
Self-citationMelanoma: Clinical Features and Genomic InsightsPreprint
Hawryluk, E. B., & Tsao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015388 · Cited by 59
Martin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54
Kawaguchi, K., Igarashi, K., Murakami, T., Zhao, M. D., Zhang, Y., Chmielowski, B., Kiyuna, T., Nelson, S. D., Russell, T. A., Dry, S., et al. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25886 · Cited by 54
Self-citationVendramin, R., Katopodi, V., Cinque, S., Konnova, A., Knezevic, Z., Adnane, S., Verheyden, Y., Karras, P., Demesmaeker, E., Bosisio, F. M., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210571 · Cited by 59
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition
Mok, S., Tsoi, J., Koya, R. C., Hu‐Lieskovan, S., West, B. L., Bollag, G. E., Graeber, T. G., & Ribas, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1377-8 · Cited by 54
Self-citationBradish, J. R., & Liang Cheng, C. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.04.001 · Cited by 54
Ultraviolet light and melanoma
Craig, S., Earnshaw, C. H., & Virós, A. (2018) · The Journal of Pathology · doi:10.1002/path.5039 · Cited by 56
Targeting BRAF in melanoma: Biological and clinical challenges
Mandalà, M., & Voit, C. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.01.003 · Cited by 56
Advances in targeted therapy for unresectable melanoma: New drugs and combinations
Hao, M., Song, F., Du, X., Wang, G., Yang, Y. P., Chen, K., & Yang, J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.050 · Cited by 56
Sundstrøm, T., Daphu, I., WENDELBO, I. H., Hodneland, E., Lundervold, A., Immervoll, H., Skaftnesmo, K. O., Babič, M., Jendelová, P., Syková, E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3514 · Cited by 53
Oncogenes in melanoma: An update
Kunz, M. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.12.002 · Cited by 55
Activating BRAF V600E Mutation in Aggressive Pediatric Langerhans Cell Histiocytosis
Méhes, G., Irsai, G., Bedekovics, J., Beke, L., Fazakas, F., Rózsa, T., & Kiss, C. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000304 · Cited by 53
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Bagrodia, S., Smeal, T., & Abraham, R. T. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12007 · Cited by 56
Trametinib (GSK1120212) in the treatment of melanoma
Salama, A. K. S., & Kim, K. B. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.770475 · Cited by 56
Self-citationPanniculitis in Patients Treated With BRAF Inhibitors
Choy, B., Chou, S., Anforth, R. M., & Fernández‐Peñas, P. (2014) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000023 · Cited by 53
Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma
Mor, J. M., & Heindl, L. M. (2016) · Ocular Oncology and Pathology · doi:10.1159/000452473 · Cited by 53
Peng, L., Wang, Y., Hong, Y. K., Ye, X., Shi, P., Zhang, J., & Zhao, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.21059 · Cited by 56
Medical Management of Cushing’s Syndrome: Current and Emerging Treatments
Hinojosa‐Amaya, J. M., Ramos, D. C., & Fleseriu, M. (2019) · Drugs · doi:10.1007/s40265-019-01128-7 · Cited by 53
Cachin, F., Miot-Noirault, E., Gillet, B., Isnardi, V., Labeille, B., Payoux, P., Meyer, N., Cammilleri, S., Gaudy‐Marqueste, C., Razzouk‐Cadet, M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.123554 · Cited by 55
Jia, P., Jin, H., Meador, C. B., Xia, J., Ohashi, K., Liu, L., Pirazzoli, V., Dahlman, K. B., Politi, K. A., Michor, F., et al. (2013) · Genome Research · doi:10.1101/gr.152322.112 · Cited by 54
Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches
Strickler, J. H., Wu, C. S.-Y., & Bekaii‐Saab, T. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.006 · Cited by 53
Inhibition of mutant BRAF splice variant signaling by next‐generation, selective RAF inhibitors
Basile, K. J., Le, K., Hartsough, E. J., & Aplin, A. E. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12218 · Cited by 53
BRAF V600 mutations and pathological features in Japanese melanoma patients
Yamazaki, N., Tanaka, R., Tsutsumida, A., Namikawa, K., Eguchi, H., Omata, W., Oashi, K., Ogawa, T., Hayashi, A., Nakamura, N., et al. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000091 · Cited by 53
Ascierto, P. A., Atkins, M. B., Bifulco, C. B., Botti, G., Cochran, A. J., Davies, M. A., Demaria, S., Dummer, R., Ferrone, S., Formenti, S. C., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0736-1 · Cited by 53
Self-citationFunck‐Brentano, E., Alvarez, J., Longvert, C., Abé, E., Beauchet, A., Funck‐Brentano, C., & Saïag, P. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv189 · Cited by 55
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
Khattak, M. A., Fisher, R. A., Turajlic, S., & Larkin, J. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012466280 · Cited by 53
Andrews, M. C., Behren, A., Chionh, F. J. M., Mariadason, J. M., Vella, L. J., Do, H., Dobrovic, A., Tebbutt, N. C., & Cebon, J. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4118 · Cited by 53
BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Vido, M. J., Le, K., Hartsough, E. J., & Aplin, A. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.049 · Cited by 55
Kramkimel, N., Thomas‐Schoemann, A., Sakji-Dupré, L., Golmard, J. L., Noé, G., Regnier-Rosencher, E., Chapuis, N., Maubec, E., Vidal, M., Avril, M., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0375-8 · Cited by 53
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4
Fischer, A., Rosen, A. C., Ensslin, C. J., Wu, S., & Lacouture, M. E. (2013) · Dermatologic Therapy · doi:10.1111/dth.12027 · Cited by 51
Variations of BRAF mutant allele percentage in melanomas
Hélias‐Rodzewicz, Z., Funck‐Brentano, E., Baudoux, L., Jung, C. K., Zimmermann, U. S., Marin, C., Clérici, T., Gall, C. L., Peschaud, F., Taly, V., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1515-3 · Cited by 51
Arnedos, M., Vielh, P. R., Soria, J., & André, F. (2013) · The Journal of Pathology · doi:10.1002/path.4276 · Cited by 51
Roulstone, V., Pedersen, M., Kyula, J., Mansfield, D., Khan, A., McEntee, G., Wilkinson, M., Karapanagiotou, E. M., Coffey, M. C., Marais, R., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.15 · Cited by 51
Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma
Curry, J. L., Torres-Cabala, C. A., Tetzlaff, M. T., Bowman, C., & Prieto, V. G. (2012) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2012.07.007 · Cited by 51
Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
Gowda, R., Madhunapantula, S. V., Kuzu, O. F., Sharma, A. K., & Robertson, G. P. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0867 · Cited by 51
Wada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113217 · Cited by 50
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
Lheure, C., Kramkimel, N., Franck, N., Laurent‐Roussel, S., Carlotti, A., Quéant, A., Goldwasser, F., Avril, M., & Dupin, N. (2015) · Dermatology · doi:10.1159/000439400 · Cited by 50
Melanoma‐associated leukoderma – immunology in black and white?
Naveh, H. P., Rao, U. N. M., & Butterfield, L. H. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12161 · Cited by 50
Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma
Boyd, K. P., Vincent, B. J., Andea, A. A., Conry, R. M., & Hughey, L. C. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.06.045 · Cited by 50
Park, J. J., Hawryluk, E. B., Tahan, S. R., Flaherty, K. T., & Kim, C. C. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.7919 · Cited by 50
Self-citationXing, M., Prajapati, H. J., Dhanasekaran, R., Lawson, D. H., Kokabi, N., Eaton, B. R., & Kim, H. S. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000109 · Cited by 50
Paradoxical oncogenesis: are all BRAF inhibitors equal?
Menzies, A. M., Kefford, R. F., & Long, G. V. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12132 · Cited by 50
Self-citationMolecular predictors of outcome in low-grade glioma
Weiler, M., & Wick, W. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a0217 · Cited by 50
Chien, A. J., Haydu, L. E., Biechele, T. L., Kulikauskas, R. M., Rizos, H., Kefford, R. F., Scolyer, R. A., Moon, R. T., & Long, G. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094748 · Cited by 50
Self-citationTreatment of brain metastases in the modern genomic era
Dagogo‐Jack, I., Gill, C. M., Cahill, D. P., Santagata, S., & Brastianos, P. K. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.011 · Cited by 50
Antonello, Z. A., Hsu, N. Y.-H., Bhasin, M., Roti, G., Joshi, M., Hummelen, P. V., Ye, E., Lo, A. S., Karumanchi, S. A., Bryke, C. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21262 · Cited by 51
MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention
Thyagarajan‐Sahu, A., Shaban, A., & Sahu, R. P. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242636 · Cited by 50
Principles of Medical Oncology
Hait, W. N., Holland, J. F., Frei, E., Kufe, D. W., Bast, R. C., & Hong, W. K. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm046 · Cited by 50
Lubrano, S., Cervantes‐Villagrana, R. D., Faraji, F., Ramirez, S. I., Sato, K., Adame-Garcia, S. R., Officer, A., Arang, N., Rigiracciolo, D. C., Quiroz, P. Y. A., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.001 · Cited by 51
Menzies, A. M., Wilmott, J. S., Drummond, M., Lo, S., Lyle, M. K., Chan, M. M. K., Thompson, J. F., Guminski, A. D., Carlino, M. S., Scolyer, R. A., et al. (2015) · Cancer · doi:10.1002/cncr.29586 · Cited by 50
Self-citationFrederick, D. T., Fragomeni, R. A. S., Schalck, A. P., Ferreiro-Neira, I., Hoff, T., Cooper, Z. A., Haq, R., Panka, D. J., Kwong, L. N., Davies, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101286 · Cited by 50
Self-citationSystemic Therapy of Brain Metastases
Brastianos, H. C., Cahill, D. P., & Brastianos, P. K. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0518-9 · Cited by 50
Economic burden of toxicities associated with treating metastatic melanoma in eight countries
Wehler, E., Zhao, Z., Bilir, S. P., Munakata, J., & Barber, B. (2015) · The European Journal of Health Economics · doi:10.1007/s10198-015-0757-y · Cited by 49
Mandalà, M., Logu, F. D., Merelli, B., Nassini, R., & Massi, D. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.132 · Cited by 50
Lessons learned in linking PROTACs from discovery to the clinic
Pike, A., Lee, E. C. Y., Michaelides, I. N., Schade, M., Sharma, A., Scott, J. S., & Srivastava, A. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00784-6 · Cited by 54
Metadata
- Authors
- Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K. D., Amaravadi, R. K., Chmielowski, B., Lawrence, H. J., Shyr, Y., Ye, F., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K., & Ribas, A.
- Affiliations
- Vanderbilt University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Abramson Cancer Center (US)
- University of Colorado Denver (US)
- New York University (US)
- Moffitt Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- University of Newcastle Australia (AU)
- Melanoma Institute Australia (AU)
- Vanderbilt-Ingram Cancer Center (US)
- University of California, Los Angeles (US)
- Vanderbilt University Medical Center (US)
- Plexxikon (United States) (US)
- ORCID
- Sosman, Jeffrey A.
- Kim, Kevin B.
- Schuchter, Lynn
- Gonzalez, Rene
- Pavlick, Anna C.
- Weber, Jeffrey S.
- McArthur, Grant A.
- Hutson, Thomas E.
- Moschos, Stergios J.
- Flaherty, Keith T.
- Hersey, Peter
- Kefford, Richard
- Lawrence, Donald
- Puzanov, Igor
- Lewis, Karl D.
- Amaravadi, Ravi K.
- Chmielowski, Bartosz
- Shyr, Yu
- Ye, Fei
- Li, Jiang
- Lee, Richard J.
- Ribas, Antoni
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-23
- Volume
- 366
- Issue
- 8
- Pages
- 707-714
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3724515
- OpenAlex
- W2168143310
- Cited by
- 2,156
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 56 · 2023: 85 · 2022: 113 · 2021: 88 · 2020: 110 · 2019: 109 · 2018: 132 · 2017: 171 · 2016: 198 · 2015: 258 · 2014: 318 · 2013: 306 · 2012: 160
- FWCI
- 133.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (K24CA097588, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, metastatic melanoma, BRAF inhibitors, overall survival, overall response rate, duration of response, progression-free survival, cutaneous squamous cell carcinoma, keratoacanthoma, adverse events
- MeSH terms
- Vemurafenib, Adult, Aged, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Sulfonamides, Treatment Outcome, Disease Progression, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
